ALZN vs. CING, OGEN, NEXI, SNPX, LIPO, CPHI, PTPI, XCUR, ARTL, and DRUG
Should you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Cingulate (CING), Oragenics (OGEN), NexImmune (NEXI), Synaptogenix (SNPX), Lipella Pharmaceuticals (LIPO), China Pharma (CPHI), Petros Pharmaceuticals (PTPI), Exicure (XCUR), Artelo Biosciences (ARTL), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical preparations" industry.
Cingulate (NASDAQ:CING) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, community ranking, valuation and profitability.
Cingulate presently has a consensus target price of $8.00, suggesting a potential upside of 812.62%. Given Alzamend Neuro's higher probable upside, analysts plainly believe Cingulate is more favorable than Alzamend Neuro.
Alzamend Neuro's return on equity of 0.00% beat Cingulate's return on equity.
In the previous week, Cingulate had 3 more articles in the media than Alzamend Neuro. MarketBeat recorded 5 mentions for Cingulate and 2 mentions for Alzamend Neuro. Cingulate's average media sentiment score of 0.00 beat Alzamend Neuro's score of -0.04 indicating that Alzamend Neuro is being referred to more favorably in the news media.
Alzamend Neuro is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.
41.3% of Cingulate shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 38.4% of Cingulate shares are owned by company insiders. Comparatively, 52.2% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Cingulate has a beta of -0.87, indicating that its stock price is 187% less volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500.
Cingulate received 2 more outperform votes than Alzamend Neuro when rated by MarketBeat users. However, 100.00% of users gave Alzamend Neuro an outperform vote while only 66.67% of users gave Cingulate an outperform vote.
Summary
Alzamend Neuro beats Cingulate on 8 of the 14 factors compared between the two stocks.
Get Alzamend Neuro News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alzamend Neuro Competitors List
Related Companies and Tools
